These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 37095347)
41. mRNA vaccines for COVID-19: what, why and how. Park JW; Lagniton PNP; Liu Y; Xu RH Int J Biol Sci; 2021; 17(6):1446-1460. PubMed ID: 33907508 [TBL] [Abstract][Full Text] [Related]
42. Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection. Kang CK; Shin HM; Choe PG; Park J; Hong J; Seo JS; Lee YH; Chang E; Kim NJ; Kim M; Kim YW; Kim HR; Lee CH; Seo JY; Park WB; Oh MD BMC Med; 2022 May; 20(1):181. PubMed ID: 35508998 [TBL] [Abstract][Full Text] [Related]
44. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH Elife; 2022 Feb; 11():. PubMed ID: 35191378 [TBL] [Abstract][Full Text] [Related]
45. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study. Akahata W; Sekida T; Nogimori T; Ode H; Tamura T; Kono K; Kazami Y; Washizaki A; Masuta Y; Suzuki R; Matsuda K; Komori M; Morey AL; Ishimoto K; Nakata M; Hasunuma T; Fukuhara T; Iwatani Y; Yamamoto T; Smith JF; Sato N Cell Rep Med; 2023 Aug; 4(8):101134. PubMed ID: 37586325 [TBL] [Abstract][Full Text] [Related]
46. Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023. Plumb ID; Briggs Hagen M; Wiegand R; Dumyati G; Myers C; Harland KK; Krishnadasan A; James Gist J; Abedi G; Fleming-Dutra KE; Chea N; Lee JE; Kellogg M; Edmundson A; Britton A; Wilson LE; Lovett SA; Ocampo V; Markus TM; Smithline HA; Hou PC; Lee LC; Mower W; Rwamwejo F; Steele MT; Lim SC; Schrading WA; Chinnock B; Beiser DG; Faine B; Haran JP; Nandi U; Chipman AK; LoVecchio F; Eucker S; Femling J; Fuller M; Rothman RE; Curlin ME; Talan DA; Mohr NM; Vaccine; 2024 Apr; 42(10):2543-2552. PubMed ID: 37973512 [TBL] [Abstract][Full Text] [Related]
47. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632 [TBL] [Abstract][Full Text] [Related]
48. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. Zhao H; Wang TC; Li XF; Zhang NN; Li L; Zhou C; Deng YQ; Cao TS; Yang G; Li RT; Huang YJ; Li YG; Zhang YM; Li FX; Zhou YR; Jiang YH; Lu XS; Sun SH; Cheng ML; Gu KP; Zhang M; Ma QQ; Yang X; Ying B; Gao YW; Qin CF Signal Transduct Target Ther; 2021 Dec; 6(1):438. PubMed ID: 34952914 [TBL] [Abstract][Full Text] [Related]
49. Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants. Fan F; Zhang X; Zhang Z; Ding Y; Wang L; Xu X; Pan Y; Gong FY; Jiang L; Kang L; Ha Z; Lu H; Hou J; Kou Z; Zhao G; Wang B; Gao XM Emerg Microbes Infect; 2023 Dec; 12(1):2202269. PubMed ID: 37038652 [TBL] [Abstract][Full Text] [Related]
50. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735 [TBL] [Abstract][Full Text] [Related]
52. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination? Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T Viruses; 2022 May; 14(5):. PubMed ID: 35632698 [TBL] [Abstract][Full Text] [Related]
53. DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study. Toyama K; Eto T; Takazawa K; Shimizu S; Nakayama T; Furihata K; Sogawa Y; Kumazaki M; Jonai N; Matsunaga S; Takeshita F; Yoshihara K; Ishizuka H Vaccine; 2023 Aug; 41(38):5525-5534. PubMed ID: 37586958 [TBL] [Abstract][Full Text] [Related]
54. mRNA vaccines for COVID-19 and diverse diseases. Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783 [TBL] [Abstract][Full Text] [Related]
55. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
56. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Hoffmann MAG; Yang Z; Huey-Tubman KE; Cohen AA; Gnanapragasam PNP; Nakatomi LM; Storm KN; Moon WJ; Lin PJC; West AP; Bjorkman PJ Cell; 2023 May; 186(11):2380-2391.e9. PubMed ID: 37146611 [TBL] [Abstract][Full Text] [Related]
57. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles. Wang J; Zhang Y; Dong S; Zha W; Liu C; Wang Y; Jiang Y; Xing H; Li X Int J Pharm; 2023 Jul; 642():123155. PubMed ID: 37402442 [TBL] [Abstract][Full Text] [Related]